GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1250
- Registration Number
- NCT04707391
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Substance P Challenge in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT04676763
- Locations
- 🇳🇱
GSK Investigational Site, Leiden, Netherlands
Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 108
- Registration Number
- NCT04676724
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1213
- Registration Number
- NCT04657211
- Locations
- 🇩🇪
GSK Investigational Site, Hannover, Germany
Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT04657198
- Locations
- 🇧🇪
GSK Investigational Site, Wilrijk, Belgium
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 758
- Registration Number
- NCT04655976
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 259
- Registration Number
- NCT04640311
- Locations
- 🇺🇸
GSK Investigational Site, Austin, Texas, United States
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT04641247
- Locations
- 🇪🇸
GSK Investigational Site, Marid, Spain
Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 169
- Registration Number
- NCT04607005
- Locations
- 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation
A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10578
- Registration Number
- NCT04605159
- Locations
- 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom